TW200716152A - Substituted 1,2-ethylendiamines, medicaments comprising said compound, their use and their method of manufacture - Google Patents

Substituted 1,2-ethylendiamines, medicaments comprising said compound, their use and their method of manufacture

Info

Publication number
TW200716152A
TW200716152A TW095110860A TW95110860A TW200716152A TW 200716152 A TW200716152 A TW 200716152A TW 095110860 A TW095110860 A TW 095110860A TW 95110860 A TW95110860 A TW 95110860A TW 200716152 A TW200716152 A TW 200716152A
Authority
TW
Taiwan
Prior art keywords
substituted
ethylendiamines
medicaments
manufacture
compound
Prior art date
Application number
TW095110860A
Other languages
English (en)
Chinese (zh)
Inventor
Christian Eickmeier
Stefan Peters
Klaus Fuchs
Niklas Heine
Sandra Handschuh
Cornelia Dorner-Ciossek
Klaus Klinder
Marcus Kostka
Original Assignee
Boehringer Ingelheim Int
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Boehringer Ingelheim Int filed Critical Boehringer Ingelheim Int
Publication of TW200716152A publication Critical patent/TW200716152A/zh

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides
    • C07K5/06008—Dipeptides with the first amino acid being neutral
    • C07K5/06017—Dipeptides with the first amino acid being neutral and aliphatic
    • C07K5/06026—Dipeptides with the first amino acid being neutral and aliphatic the side chain containing 0 or 1 carbon atom, i.e. Gly or Ala
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides
    • C07K5/06008—Dipeptides with the first amino acid being neutral
    • C07K5/06017—Dipeptides with the first amino acid being neutral and aliphatic
    • C07K5/06034—Dipeptides with the first amino acid being neutral and aliphatic the side chain containing 2 to 4 carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides
    • C07K5/06191—Dipeptides containing heteroatoms different from O, S, or N
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/08—Tripeptides
    • C07K5/0802—Tripeptides with the first amino acid being neutral
    • C07K5/0804—Tripeptides with the first amino acid being neutral and aliphatic
    • C07K5/0808—Tripeptides with the first amino acid being neutral and aliphatic the side chain containing 2 to 4 carbon atoms, e.g. Val, Ile, Leu
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/08—Tripeptides
    • C07K5/0802—Tripeptides with the first amino acid being neutral
    • C07K5/0812—Tripeptides with the first amino acid being neutral and aromatic or cycloaliphatic
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/08—Tripeptides
    • C07K5/0821—Tripeptides with the first amino acid being heterocyclic, e.g. His, Pro, Trp

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Diabetes (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Emergency Medicine (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Endocrinology (AREA)
  • Oncology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Peptides Or Proteins (AREA)
TW095110860A 2005-03-30 2006-03-29 Substituted 1,2-ethylendiamines, medicaments comprising said compound, their use and their method of manufacture TW200716152A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP05006939 2005-03-30

Publications (1)

Publication Number Publication Date
TW200716152A true TW200716152A (en) 2007-05-01

Family

ID=36545049

Family Applications (1)

Application Number Title Priority Date Filing Date
TW095110860A TW200716152A (en) 2005-03-30 2006-03-29 Substituted 1,2-ethylendiamines, medicaments comprising said compound, their use and their method of manufacture

Country Status (7)

Country Link
US (3) US7713961B2 (cg-RX-API-DMAC7.html)
EP (1) EP1866034A1 (cg-RX-API-DMAC7.html)
JP (1) JP2008534541A (cg-RX-API-DMAC7.html)
AR (1) AR056862A1 (cg-RX-API-DMAC7.html)
CA (1) CA2603404A1 (cg-RX-API-DMAC7.html)
TW (1) TW200716152A (cg-RX-API-DMAC7.html)
WO (1) WO2006103038A1 (cg-RX-API-DMAC7.html)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1866034A1 (en) * 2005-03-30 2007-12-19 Boehringer Ingelheim International GmbH Substituted 1,2-ethylendiamines, medicaments comprising said compound; their use and their method of manufacture
CA2617294A1 (en) * 2005-08-03 2007-02-08 Boehringer Ingelheim International Gmbh Substituted ethane-1,2-diamines for the treatment of alzheimer's disease ii
WO2007017511A2 (de) * 2005-08-11 2007-02-15 Boehringer Ingelheim International Gmbh Verbindungen zur behandlung der alzheimer erkrankung
JP2009504612A (ja) * 2005-08-11 2009-02-05 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング アルツハイマー病の治療用化合物
EP1915339A1 (de) * 2005-08-11 2008-04-30 Boehringer Ingelheim International GmbH Inhibitoren der beta-sekretase zur behandlung der alzheimer- erkrankung
US20100168070A1 (en) * 2005-08-11 2010-07-01 Niklas Heine Compounds for the treatment of alzheimer's disease
WO2010042796A1 (en) 2008-10-10 2010-04-15 Purdue Research Foundation Compounds for treatment of alzheimer's disease
CA2744425A1 (en) 2008-11-20 2010-05-27 Purdue Research Foundation Quinazoline inhibitors of bace 1 and methods of using
WO2010065861A2 (en) * 2008-12-05 2010-06-10 Purdue Research Foundation Inhibitors of bace 1 and methods for treating alzheimer's disease
WO2011044057A1 (en) * 2009-10-05 2011-04-14 Comentis, Inc. Sulfonamido pyrrolidine compounds which inhibit beta-secretase activity and methods of use thereof
US20140066488A1 (en) * 2012-08-30 2014-03-06 Purdue Research Foundation Inhibitors of Memapsin 2 Cleavage for the Treatment of Alzheimer's Disease
BR112023026747A2 (pt) 2021-06-18 2024-03-12 Aligos Therapeutics Inc Métodos e composições para direcionamento de pd-l1
CN119212987A (zh) 2021-12-16 2024-12-27 安力高医药股份有限公司 用于靶向pd-l1的方法和组合物

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CZ184194A3 (en) 1993-08-09 1995-03-15 Lilly Co Eli Aspartylprotease inhibitor and method of identifying thereof
US7087399B1 (en) 1999-05-13 2006-08-08 Scios, Inc. β-secretase and modulation of β-secretase activity
JP5138851B2 (ja) 1999-06-28 2013-02-06 オクラホマ メディカル リサーチ ファウンデーション 触媒的に活性な組換えメマプシンおよびその使用方法
WO2002100410A1 (en) * 2001-06-08 2002-12-19 Elan Pharmaceuticals, Inc. Methods of treating alzheimer's disease
WO2003032994A2 (de) 2001-10-17 2003-04-24 Boehringer Ingelheim Pharma Gmbh & Co. Kg 5-substituierte 4-amino-2-phenylamino-pyrimidinderivate und ihre verwendung als beta-amyloid modulatoren
CA2472617A1 (en) * 2002-01-04 2003-07-17 Elan Pharmaceuticals, Inc. Substituted amino carboxamides for the treatment of alzheimer's disease
BR0314714A (pt) * 2002-09-27 2005-08-02 Elan Pharm Inc Compostos para o tratamento da doença de alzheimer
WO2004043916A1 (en) * 2002-11-12 2004-05-27 Merck & Co., Inc. Phenylcarboxamide beta-secretase inhibitors for the treatment of alzheimer's disease
US20050090449A1 (en) 2003-05-13 2005-04-28 Boehringer Ingelheim International Gmbh Novel statine derivatives for the treatment of Alzheimer's disease
EP1641748B1 (en) * 2003-06-30 2013-08-28 Merck Sharp & Dohme Corp. N-alkyl phenylcarboxamide beta-secretase inhibitors for the treatment of alzheimer s disease
JP2007538024A (ja) 2004-05-19 2007-12-27 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング アミロイドベータペプチドのレベル変化に関連する疾患及び状態の治療方法及び新規エノールカルボキサミド化合物
WO2005113582A1 (en) 2004-05-22 2005-12-01 Boehringer Ingelheim International Gmbh Substituted ethane-1,2-diamines for the treatment of alzheimer's disease
WO2006050862A1 (en) 2004-11-10 2006-05-18 Boehringer Ingelheim International Gmbh Statine derivatives for the treatment of alzheimer's disease
WO2006050861A2 (en) 2004-11-10 2006-05-18 Boehringer Ingelheim International Gmbh Statine derivatives for the treatment of alzheimer's disease
EP1866034A1 (en) * 2005-03-30 2007-12-19 Boehringer Ingelheim International GmbH Substituted 1,2-ethylendiamines, medicaments comprising said compound; their use and their method of manufacture
CA2617294A1 (en) 2005-08-03 2007-02-08 Boehringer Ingelheim International Gmbh Substituted ethane-1,2-diamines for the treatment of alzheimer's disease ii
JP2009504612A (ja) 2005-08-11 2009-02-05 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング アルツハイマー病の治療用化合物

Also Published As

Publication number Publication date
US7713961B2 (en) 2010-05-11
US20060223759A1 (en) 2006-10-05
EP1866034A1 (en) 2007-12-19
JP2008534541A (ja) 2008-08-28
US20100204160A1 (en) 2010-08-12
WO2006103038A1 (en) 2006-10-05
US20090325940A1 (en) 2009-12-31
AR056862A1 (es) 2007-10-31
CA2603404A1 (en) 2006-10-05

Similar Documents

Publication Publication Date Title
NL300933I2 (nl) Letermovir
TW200738242A (en) Dihydropteridinones in the treatment of respiratory diseases
UA83691C2 (ru) Применение замещенных 2-аминотетралинов для упреждающего лечения болезни паркинсона
EA200401114A2 (ru) Замещённые гидроксиэтиламины
DK1689721T3 (da) Aminopyrazolderivater som GSK-3-ihibitorer
WO2005037798A3 (en) Amide or thiomide derivatives and their use in the treatment of pain
WO2009007300A3 (en) Substituted amino-quinazolinones, medicaments comprising said compound, their use and their method of manufacture
IL183636A0 (en) Quinoline derivative, use and production thereof, and drug containing the same
TW200630374A (en) Thiazolyldihydroindazoles
ATE409480T1 (de) Pyrazoloä3,4-büpyridin-6-one als gsk-3 inhibitoren
TW200716152A (en) Substituted 1,2-ethylendiamines, medicaments comprising said compound, their use and their method of manufacture
TW200604196A (en) New quinuclidine derivatives and pharmaceutical compositions comprising them
CY1110401T1 (el) Παραγωγα των 1-φαινυλαλκανοκαρβοξυλικων οξεων για την αντιμετωπιση των νευροεκφυλιστικων νοσων
WO2006055434A3 (en) Macrocyclic tertiary amine beta-secretase inhibitors for the treatment of alzheimer's disease
SE0400708D0 (sv) New compounds and use thereof
WO2008023003A8 (de) Arzneimittelkombinationen zur behandlung von atemwegserkrankungen
TW200640911A (en) Novel, long acting betamimetics for the treatment of respiratory diseases
WO2007017511A3 (de) Verbindungen zur behandlung der alzheimer erkrankung
WO2006050861A3 (en) Statine derivatives for the treatment of alzheimer's disease
UA86399C2 (ru) Применение 2,5 дигидроксибензолсульфоновой кислоты для изготовления лекарства, которые применяют для лечения болезней, зависимых от ангиогенеза
TW200635595A (en) Medicaments for the treatment of prevention of fibrotic diseases
MY146802A (en) Novel drugs for treating respiratory diseases
WO2007017510A3 (de) Isophthalsäurediamide zur behandlung der alzheimer erkrankung
ATE524171T1 (de) Verwendung von 2-(2-nitro-4- trifluormethylbenzoyl)-1,3-cyclohexandion bei der behandlung der parkinson-krankheit
ATE407126T1 (de) Herstellung von (s)-4-fluormethyl-dihydro-furan-2-on